“Don’t Be a Viking”: Campaign Plays on Dupuytren’s Nickname to Illustrate Patient Journey
Health & PatientsClick to watch the commercial.
Keenova’s new national campaign, Don’t Be a Viking, aims to motivate people with Dupuytren’s contracture to talk with a hand specialist early and learn about nonsurgical treatment options.
Why It Matters
Dupuytren’s contracture affects an estimated 13 million Americans.1,2* Keenova’s research shows that many delay care to avoid surgery or simply adapt to the condition instead of addressing it.3†
A Bold Creative Choice
The campaign concept leans into the condition’s nickname, “Viking Hand,” which stems from a historic genetic link to Northern European ancestry. Today the condition is far more widespread, but the Viking metaphor provides a powerful image to illustrate the journey from confusion to action.
The commercial follows that arc. The Viking struggles, then finally takes control by seeking help from a hand specialist.
Driving the Message Home
The new commercial opens with a Viking in his kitchen wrestling with a jar of pickles. The scene captures the everyday frustration many patients feel when their fingers can no longer straighten. The spot highlights a simple truth: Once someone cannot lay their hand flat, it’s time to see a hand specialist and discuss nonsurgical treatment.
Dupuytren’s contracture is a progressive condition caused by a buildup of collagen in the hand that forms a rope-like cord pulling fingers toward the palm. As it progresses, it may become difficult for individuals to use their hand(s) for daily tasks and activities.4,5
Call to Action
Don’t Be a Viking encourages people with Dupuytren’s contracture symptoms, along with their loved ones and caregivers, to visit FindaHandSpecialist.com. The website connects individuals with hand specialists who can diagnose the condition and walk through the full range of treatment options, including nonsurgical approaches.
The message is clear: Don’t Be a Viking. Real strength comes from taking control early and partnering with a trusted hand specialist.
* Dupuytren’s contracture prevalence estimation calculation in the U.S.: Average Dupuytren’s contracture prevalence in the U.S. (5%) multiplied by U.S. adult population (~258 million adults per 2020 U.S. Census data) = ~13 million.
† Data sourced from 2024 consumer market research based on a web-based survey of 200 adults who were either diagnosed with Dupuytren's contracture or believe they have Dupuytren's contracture based on a detailed description of symptoms.
References
- MedlinePlus Genetics. Dupuytren contracture. National Library of Medicine. Accessed April 21, 2026. https://medlineplus.gov/genetics/condition/dupuytren-contracture/#frequency
- Ogunwole SU, Rabe MA, Roberts AW, Caplan Z. Adult population grew faster than total population from 2010 to 2020. U.S. Census Bureau. Published August 12, 2021. Accessed April 21, 2026. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html
- Endo USA, Inc., a Keenova Therapeutics company. Dupuytren's Contracture Consumer Awareness Trial Usage Online Survey Report. 2024.
- Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10),968-979.
- Bayat A, McGrouther DA. Management of Dupuytren’s disease--clear advice for an elusive condition. Ann R Coll Surg Engl. 2006;88(1):3-8.
